Significantly, CCL5 expression was able to distinguish poor prognosis and progressiveness in patients with kidney renal clear cell carcinoma (KIRC), brain lower-grade glioma (LGG), sarcoma (SARC), skin cutaneous melanoma (SKCM), uterine corpus endometrial carcinoma (UCEC), and uveal melanoma (UVM) among others (P<0.05; Supplementary Figure 3A-B). This evidence concerns the gene CCL5 and uveal melanoma.